Piotr J. Wysocki: Pembrolizumab significantly improves efficacy of chemoradiotherapy in patients with locally-advanced cervical cancer
Piotr J. Wysocki, Head of the Oncology Department at the
“Results of a phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 have been just published in the Lancet. The study randomized 1060 patients with newly diagnosed, high-risk, locally advanced cervical cancer in a 1:1 ratio to receive pembrolizumab or placebo combined with chemoradiotherapy, followed by pembrolizumab or placebo administered for approx. 21 months. Chemoradiotherapy was based on weekly cisplatin (40 mg/m2) plus external beam radiotherapy followed by brachytherapy. Primary endpoints were progression-free survival (PFS) and overall survival (OS).
With a median follow-up of 17.9 months median PFS was not reached in either group. The 24-month PFS rates were 68% in the pembrolizumab+chemoradiotherapy group and 57% in the placebo+chemoradiotherapy group. Chemoradiotherapy combined with pembrolizumab resulted in significantly decreased risk of progression or death by 30% – (HR for PFS – 0.70; 95% CI 0·55–0·89). Overall survival at 24 months was 87% in the experimental arm and 81% in the control arm (HR for OS – 0.73; 95%CI 0.49–1.07) and these data have not crossed the prespecified boundary of statistical significance.
Despite the fact, that survival data from ENGOT-cx11/GOG-3047/KEYNOTE-A18 are still relatively immature, pembrolizumab should be considered a standard option in high-risk patients undergoing chemoradiotherapy with curative intent.”
Read the article.
Source: Piotr J. Wysocki/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023